该专科学科带头人王昊是汕头市中心医院党委书记、暨南大学博士生导师，同时也是"广东特支计划"科 技创新领军人才，在慢性病研究、重大科研项目承担及高水平学术成果产出方面建树颇丰，带领该院团 队承担了包括国家重点研发计划、国家自然科学基金在内的多项国家级、省部级课题，并积极推动科技 成果转化，主编教材、获得专利多项，形成了医、教、研相互促进的良好局面。 国家临床重点专科由国家卫生健康委评估认定，代表我国医疗技术和服务能力最高水平的顶尖临床专科 类别。其核心特征是医疗服务能力突出、医疗质量控制严格、科研教学体系完善、管理运作规范高效。 此次入选，不仅是对汕头市中心医院全科医学科"硬实力"的权威认证，更意味着该专科将迎来新一轮的 发展机遇。 汕头市中心医院全科医学科起步早、基础实、模式新。早在2013年，学科成为国家首批全科医生规范化 培训基地建设项目，2014年获批国家级住院医师规范化培训基地，是粤东地区最早、规模最大、实力最 为雄厚的全科医学优势学科之一，也是粤东全科医学人才的核心培养基地。 作为此次全省唯一入选的全科医学科，其创新构建的"医院—社区—家庭"联动全科医疗综合防治与管理 模式，通过紧密型医联体合作，实 ...

Core Viewpoint - 盈健医疗 (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to shareholders was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in revenue from general medical services, specialized medical services, and dental services [1] - The gross profit also increased, attributed to the overall revenue growth [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a revenue of approximately HKD 644 million for the fiscal year 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year increase of about 8.9% [1] - The board proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, up from HKD 0.028 in fiscal year 2024 [1] Revenue and Profit Growth - The company achieved a steady revenue growth despite ongoing adverse economic conditions in Hong Kong, with a revenue increase of approximately 9.1% compared to fiscal year 2024 [1] - The profit attributable to the owners increased by about 8.9% year-on-year, indicating strong financial performance [1] Business Segment Performance - The core business segments maintained balanced growth, with the primary care division showing stable performance driven by network expansion and a strong patient base [1] - The specialty medical division experienced robust revenue growth due to service upgrades and the addition of more specialists, particularly in ophthalmology, pediatric surgery, cardiology, psychiatry, and orthopedics [1] - Despite competitive pressures in the dental segment, overall revenue growth was achieved following the acquisition of Youde Dental in fiscal year 2025 [1]

Core Viewpoint - Yingjian Medical (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in general medical services, specialized medical services, and dental services [1] - Gross profit increased due to the rise in revenue [1]

Group 1 - The core stock price of Yingjian Medical (01419.HK) closed at HKD 1.110 on August 13, down 1.77% from the previous trading day, with an intraday high of HKD 1.160, marking a nearly one-year high [1] - The company experienced a net inflow of HKD 17.59 thousand on that day, with unspecified amounts flowing in and out [1] - Yingjian Medical Group Limited, established in 1997, is one of the largest medical groups in Hong Kong, listed on the Hong Kong Stock Exchange under stock code 1419 [1] Group 2 - The group operates under the brands "Human Health Integrated Medical Centre," "Human Health Medical Centre," and "Perfect Life," providing comprehensive primary healthcare services [1] - Yingjian Medical has over 60 medical centers across Hong Kong, Kowloon, the New Territories, and outlying islands, offering a wide range of services including prevention, health maintenance, diagnosis, and treatment [1] - The company aims to expand its network of medical centers and establish specialized medical service centers, adhering to its corporate culture of "benevolence" to ensure more citizens can access quality healthcare services [1]

Group 1 - The core viewpoint of the news highlights the performance of Yingjian Medical (盈健医疗) in the Hong Kong stock market, noting a significant increase in its stock price and a comparison of its financial metrics against industry averages [1] - As of July 23, the Hang Seng Index rose by 1.62%, while Yingjian Medical's stock price increased by 13.95%, closing at HKD 0.98 per share with a trading volume of 1.094 million shares [1] - Over the past month, Yingjian Medical has seen a cumulative increase of 6.17%, but it has underperformed compared to the Hang Seng Index, which has risen by 25.27% year-to-date [1] Group 2 - Financial data indicates that Yingjian Medical achieved total revenue of HKD 292 million for the year ending December 31, 2024, reflecting a year-on-year growth of 6.98%, while its net profit attributable to shareholders decreased by 16.03% to HKD 15.5778 million [1] - The company's gross profit margin stands at 47.09%, and its debt-to-asset ratio is 25.1% [1] - In terms of industry valuation, the average price-to-earnings (P/E) ratio for the healthcare equipment and services sector is -1.96x, with a median of 1.36x, while Yingjian Medical's P/E ratio is 15.56x, ranking 25th in the industry [1]